U.S. stock market midday update: MiNK Therapeutics up 8.27%

U.S. Stock Market Midday Update MiNK Therapeutics, up 8.27%, with increased trading volume. Based on recent key news: On July 15, MiNK Therapeutics announced that its experimental allogeneic cell therapy agenT-797 showed complete remission in a patient with advanced testicular cancer, causing the stock price to surge 730%. On July 15, the company submitted a $50 million stock issuance document, leading to a 23.7% drop in stock price. On July 15, MiNK Therapeutics' stock price fell 37% on Monday, closing at $40.61. Stocks with High Trading Volume in the Industry 180 Life Sciences, up 90.98%, with a trading volume of $614 million. Based on recent important news: On August 12, 180 Life Sciences announced the completion of a $156 million convertible bond issuance, with funds used to increase holdings in Ethereum, causing the stock price to soar 54% after hours. On August 12, billionaire Peter Thiel disclosed a 7.5% stake in ETHZilla, driving the stock price up over 11% in a single day. On August 11, the company announced it holds 82,186 Ethereum, valued at approximately $349 million, further boosting market confidence. Forte Pharma, up 2.64%, with a trading volume of $247 million. Based on recent key news: On August 12, analysts upgraded Forte Pharma's rating to Strong Buy, citing strong cash flow and balance sheet, which drove the stock price up 2.64%. On August 11, market expectations for Forte Pharma's future growth increased, especially in the pain management sector, further lifting the stock price. On August 10, despite a slowdown in overall biotech industry growth, Forte Pharma's unique market positioning benefited it, resulting in better stock performance than peers. Aliram Pharmaceuticals, down 0.73%, with increased trading volume. Based on recent important news: On August 11, Aliram Pharmaceuticals showcased the potential of RNAi therapy in treating cardiovascular diseases, failing to attract widespread market attention, leading to a 0.73% decline in stock price. On August 12, market analysts did not include Aliram in their recommended list, dampening investor confidence. On August 10, analysts suggested better investment options, rating Aliram as a Moderate Buy, affecting market sentiment. Stocks with High Market Capitalization in the Industry AbbVie, down 0.30%, with increased trading volume. Based on recent key news: On August 12, Piper Sandler initiated coverage on AbbVie with an Overweight rating and a target price of $231, boosting the stock price. On August 11, MarketBeat reported that AbbVie was not included in the list of top five stocks recommended by leading analysts, leading to a decline in market confidence and stock price On August 10th, MarketBeat reiterated that AbbVie was not included in the top analyst recommendations, further undermining investor confidence, and the stock price continued to decline